Member Info for gtc1507

Blue already and not much left to go further by the looks of it!

Couple of chartists suggested this would breathe before a move above 20p. Looking more positive this morning for another run!

Extremely pointless but hey more fool them! Some strength in buying into the sells today so demand clearly very strong. Holding out for those sleeves to unroll

MMs Playing tricks already this morning! Hold tight for the rebound like Friday hopefully

Just spotted a great Q&A about Fusion’s Opti-library that’s worth highlighting on their investor hub.

Someone asked if the Opti-library is one of the biggest out there, since the theoretical size is quoted as 10^45 whereas some of the largest known antibody libraries are around 10^11.

Fusion’s answer:

“A:The theoretical size of the human Opti- library is indeed 10^45 (apologies for the limited text formatting available here). We are not currently aware of a similar curated library of anything like this size. Not all of the theoretical sequences exist in a physical form as synthesized DNA – it’s just too big to do that. Each physically synthesised library is around 10^10 and we sample approximately 10^9 from this for an individual screen against a nominated target. We could do more or less than this if circumstances and budget required it, but for the time being our current model is to continue with screens of around 10^9. It is true that some other screens on other platforms are larger than this, this is common for phage display. However, as phage display is limited to fragments of antibodies, we would argue that you need more fragment hits to reach the targeted number of intact antibody leads. Those larger phage display screens often come from theoretical libraries which are only a few fold larger than the screen itself. This then presents the problem of exclusivity on a sequence and removal of hit sequences from the library. That phage display business model then causes a diminishment of the value of the library as the hit sequences eventually get removed. This is not the case for the Opti-library as we can generate 10^9 fresh sequences for each screen and each newly synthesized library is unlike the one(s) that went before.”

My read on Why this matters:

Fusion aren’t aware of a similar library of this size in the market but their approach to utilising the library and using smaller screens is what really differentiates them. This likely means Fusion isn’t just competing on raw size, they’ve got a fundamentally different (and better) business model.

Clients could get exclusivity, scalability, and a fresh run every time with greater likelihood of returning a successful candidate.

That’s potentially a major commercial advantage over traditional CROs reliant on phage display – and it’s exactly the kind of differentiator that could attract licensing deals , partnerships and drive higher value for us shareholders.

Very exciting!

And the supervisor of the paper is Professor Charlotte Deane…

For anyone not yet connecting the dots – she’s not just any academic. Professor Deane sits on Fusion Antibodies’ Scientific Advisory Panel, she’s spearheading the UK Government’s flagship AI for science programme, and she’s Chair of the Engineering and Physical Sciences Research Council (EPSRC) – one of the most influential research funding bodies in the country.

These are the kind of connections that matter. When you’re working with someone plugged into both cutting-edge science and the highest levels of government strategy, it’s not just about technical expertise – it’s about visibility, credibility, and being in the room when the big calls get made.

Fusion aren’t just playing in the biotech sandbox – they’ve got scientific heavyweights with direct lines into national research agendas, AI policy, and major funding channels. If you think that doesn’t move the needle when partnerships and strategic opportunities are on the table… you might want to think again.

High calibre science. High level connections. A platform that’s already catching the attention of the world’s biggest institutions. The market’s still treating this like a microcap.

Https://www.linkedin.com/redir/redirect?url=https%3A%2F%2Flnkd%2Ein%2FdhTk26Pf&urlhash=8kt3&trk=public_post-text

https://www.biorxiv.org/content/10.1101/2025.08.06.668938v1

This is amazing work coming from their collab with Oxford uni

Wonder will our background buyer be back today! Time for the next move upwards

We don’t need to fear a raise here. The last raise was at no discount and was taken heavily by VCT who have a long term perspective. Even a £1m cash raise would be 10% dilution at that rate and would smash them over profitability - they’ve been clear they don’t need one for working capital before break even. And optimal will smash their revenues.

The recent rise in the share price is great to see — but let’s remember why most of us are invested and what’s still ahead.

• OptiMAL® – Game-changer potential

Fusion’s world-class antibody discovery platform, about to be validated with the US National Cancer Institute, is moving toward commercial launch. This is technology that could be world-first in its scope, and it’s at the heart of why we’re here.

• Revenues & Milestones

They have a strong track record of securing potential milestone income from past deals, now licensing antibodies to clinical companies and co-developing assets with partners like Queen’s University. These aren’t just theoretical pipelines — there’s a proven history of delivering and locking in future monetisation of antibody discovery. optimal will return us to and accelerate the pipeline of entitlements.

• Prestige & Partnerships

Member of the £55m Future Medicines Institute with the likes of Randox, Almac, QUB and Ulster Unit, partnered with the most prestigious government agency in the world for oncology research (NCI), and presenting at the global Antibody Engineering & Therapeutics conference in San Diego later this year — alongside industry heavyweights.

• Financial Positioning

Fusion is now leaner than ever, close to EBITDA positive, and operating with a small, focused team — which means any revenue growth can drop quickly to the bottom line.

• Valuation Gap

Market cap of ~£15m vs peers like Absci ($c.400m) and FairJourney (€900m)valued many times higher — despite technology that arguably outperforms theirs. That’s why this is also prime takeover territory.

• On the Cusp

This is a company on the brink of a “step-change” — with a platform that can generate licensing, royalties, and co-development upside for years.

The market is still pricing them as if they’re going to fail. If they don’t, the rerate could be even more dramatic.

Bottom line: The share price action is nice, but the story is just beginning. The tech, the partnerships, the track record, and the valuation gap are why we’re here. There’s plenty more I could say (and maybe will soon 🤣), but stay focused on the destination, not just the daily moves.

#DYOR

The recent rise in the share price is great to see — but let’s remember why most of us are invested and what’s still ahead.

• OptiMAL® – Game-changer potential

Fusion’s world-class antibody discovery platform, about to be validated with the US National Cancer Institute, is moving toward commercial launch. This is technology that could be world-first in its scope, and it’s at the heart of why we’re here.

• Revenues & Milestones

They have a strong track record of securing potential milestone income from past deals, now licensing antibodies to clinical companies and co-developing assets with partners like Queen’s University. These aren’t just theoretical pipelines — there’s a proven history of delivering and locking in future monetisation of antibody discovery. optimal will return us to and accelerate the pipeline of entitlements.

• Prestige & Partnerships

Member of the £55m Future Medicines Institute with the likes of Randox, Almac, QUB and Ulster Unit, partnered with the most prestigious government agency in the world for oncology research (NCI), and presenting at the global Antibody Engineering & Therapeutics conference in San Diego later this year — alongside industry heavyweights.

• Financial Positioning

Fusion is now leaner than ever, close to EBITDA positive, and operating with a small, focused team — which means any revenue growth can drop quickly to the bottom line.

• Valuation Gap

Market cap of ~£15m vs peers like Absci ($c.400m) and FairJourney (€900m)valued many times higher — despite technology that arguably outperforms theirs. That’s why this is also prime takeover territory.

• On the Cusp

This is a company on the brink of a “step-change” — with a platform that can generate licensing, royalties, and co-development upside for years.

The market is still pricing them as if they’re going to fail. If they don’t, the rerate could be even more dramatic.

Bottom line: The share price action is nice, but the story is just beginning. The tech, the partnerships, the track record, and the valuation gap are why we’re here. There’s plenty more I could say (and maybe will soon 🤣), but stay focused on the destination, not just the daily moves.

#DYOR

Someone buying in the background, others like sponge calling it

https://x.com/themoneysponge/status/1955190373065630148?s=46

Say they locked in 2% royalties on future sales, that’s £5.5m royalty on that and then a potential 4.78p special dividend per share or reinvestment back into the business. And they are going to be building multiple products.

Or, they just have a pharma acquire their DR5 antibody asset for hundreds of millions

Fusion humanised it for Calypso in their early days but weren’t mature enough at that stage to retain milestones or royalties.

Now their model is different and includes royalties and milestones it shows what they could be entitled to:

https://www.fh-partners.com/news-entries/2024/1/8/calypso-enters-into-agreement-to-be-acquired-by-novartis

Adrian said at the proactive investors meet in January 2024 that this was one of theirs but it as too early for their development.

Now this is exactly the model they’re targeting.

You also forget this fact from his CV;

“He was formerly the Chief Commercial Officer for Promexus Ltd, a protein biotherapeutics company where he d eveloped the corporate strategy for Therapeutic Affimers, culminating in a multi-target deal with a potential of over $1bn. “

Handy to have experience landing $1bn dollar deals when you have a world first revolutionary platform that can generate a huge number of therapeutic and diagnostic antibody candidates and a company that is servicing the needs of others as well as generating its own assets for licensing…..

The only way is up! Fab play here many different angles.

Look at the AI Project they’re involve in with Oxford uni - some early pre print published results from that very promising to be at the forefront of the AI driven drug discovery with such prestigious partners

Snakes showing buys as sells

Going from -10% to -1.72% is pretty impressive

Fusion are well placed in many areas. Their AImLab service is one them. They seem to be able to partner with anyone playing in this space. chai are investing multi milllions in this space and that doesnt appear to be a competitive thing, more of an opportunity according to their view on their hub….

https://investorhub.fusionantibodies.com/7088131#question-152454

The point you raise is an interesting one – thank you for flagging it up. One of the biggest challenges with AI/ML design of antibodies is in the number of sequences which can be synthesised and used to generate the actual antibody in the real world for ‘wet-lab’ experimentation. The algorithms process huge numbers of potential theoretical sequences and, one way or another, score them according to how well the algorithm predicts it will bind to the target. The sequences can then be ranked and the top few - typically 10’s or maybe 100’s of sequences synthesised and used to generate the physical antibodies for testing. Not all of the antibodies will express, further reducing the number of samples available for testing. This severely limits the number of sequences to be tested and therefore success relies on the scoring bringing the very best antibodies to the top of the very lengthy list. With AI/ML-AbTM we can deal with libraries of antibodies. These might be a few thousand or a few million in size and offer a much deeper interrogation of the algorithm's output. Having so many more sequences to test in the real world reduces the risk for the project. It is obviously beneficial to express the sequences in mammalian cells as fully intact antibodies, which is possible with our Mammalian Display platform. Again, not all of the antibodies will express, but that doesn’t matter so much as there are so many more sequences available. In large part it is this opportunity to de-risk the project that AI/ML-AbTM offers our clients. We are able to make it available for any algorithm, whether that is commercially available or the client’s own development. We also offer clients access to algorithms by collaborating with a trusted third party who has an appropriate algorithm for that’s client’s needs. We are open to working with a wide range of third party providers in this way and that might include the US company you reference.

Https://www.linkedin.com/posts/ben-thomas-aba49119b_rnatherapeutics-cancerresearch-genomictargets-activity-7359327491175374849-QNzc?utm_source=share&utm_medium=member_ios&rcm=ACoAACft1F0BaVDaXIBn7r_8No_nNgqdtyRaz0w

Big collab for the FMI - shows the sort of thing that consortium membership lines them up for. Who knows what involvement and therefore royalty milestone entitlement the guys might have